Active, not recruitingInterventional · Phase 4NCT04835506 ↗Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
Active, not recruitingInterventional · Phase 4NCT06095128 ↗An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative ColitisDana Jeremy LukinPIInterventionDrug: Vedolizumab · Drug: TofacitinibDatesJun 2024 – Jul 2027 (est.)SponsorTakeda Development Center Americas, Inc.Ulcerative Colitis
CompletedInterventional · Phase 4NCT04259138 ↗VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment TargetDana Jeremy LukinPIInterventionBiological: Treatment Algorithm A · Biological: Treatment Algorithm B · Biological: Treatment Algorithm CDatesFeb 2020 – Apr 2026SponsorAlimentiv Inc.Colitis, Ulcerative
TerminatedInterventional · Phase 4NCT05369832 ↗A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical PracticeEllen J ScherlPIInterventionDrug: OzanimodDatesDec 2022 – Jan 2025· Results postedSponsorBristol-Myers Squibb CompanyColitis, Ulcerative